Literature DB >> 30383574

Perfusion Monitoring Shows Minimal Blood Flow From the Flap Pedicle to the Tarsoconjunctival Flap.

Kajsa Tenland1, Khashayar Memarzadeh1, Johanna Berggren1, Cu Dinh Nguyen1, Ulf Dahlstrand1, Jenny Hult1, Karl Engelsberg1, Sandra Lindstedt2, Rafi Sheikh1, Malin Malmsjö1.   

Abstract

BACKGROUND: A previous study in pigs has shown that the pedicle of the tarsoconjunctival flap does not appear to have adequate blood perfusion. The aim of this study was to monitor perfusion in tarsoconjunctival flaps in patients with large lower eyelid defects resulting from tumor surgery.
METHODS: The modified Hughes procedure was performed in 13 patients. Blood perfusion was monitored using laser Doppler velocimetry and laser speckle-contrast imaging.
RESULTS: Blood flow decreased gradually from the pedicle base to the end of the flap and was 19% at the flap base, 11% in the middle of the flap, and 4% in the distal end of the flap. The flaps survived, and there was no tissue necrosis.
CONCLUSIONS: Tarsoconjunctival tissue survival does not seem to be dependent on a conjunctival flap. Free tarsoconjunctival grafts or composite grafts might be considered as viable alternatives in reconstruction of major eyelid defects.

Entities:  

Mesh:

Year:  2019        PMID: 30383574     DOI: 10.1097/IOP.0000000000001250

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  2 in total

Review 1.  How and when of eyelid reconstruction using autologous transplantation.

Authors:  Giovanni Miotti; Marco Zeppieri; Agostino Rodda; Carlo Salati; Pier Camillo Parodi
Journal:  World J Transplant       Date:  2022-07-18

2.  Reperfusion of Free Full-Thickness Skin Grafts in Periocular Reconstructive Surgery Monitored Using Laser Speckle Contrast Imaging.

Authors:  Johanna Berggren; Nazia Castelo; Kajsa Tenland; Ulf Dahlstrand; Karl Engelsberg; Sandra Lindstedt; Rafi Sheikh; Malin Malmsjö
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2021 Jul-Aug 01       Impact factor: 1.746

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.